Teva sues CMS over Medicare drug price negotiations
Teva Pharmaceutical Industries sues CMS over Medicare drug pricing negotiations policy, claiming agency has unchecked ...
Teva's SWOT analysis: stock poised for growth as legal hurdles clear
Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...
Teva Hits Biden With New Challenge to Medicare Drug Price Talks
Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...
FiercePharma8d
Catalyst settles with Teva, staving off Firdapse generic until 2035
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
New York Post25d
FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza
Hikma’s branded generic will compete with Teva Pharmaceuticals authorized generic of Victoza in the United States that was launched earlier this year. Authorized generics are the exact copies ...
Teva Pharmaceutical’s Growth Potential and Strategic Market Positioning
Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) and increased ...
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva
Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock ...
Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva
Catalyst Pharmaceuticals (CPRX) announced that the company and its licensor SERB S.A. have entered into a Settlement Agreement with Teva ...